Table 2.
Baseline demographic and clinical characteristics (intention‐to‐treat cohort, n = 252)
| Characteristic | NEPA + DEX1 (n = 84) | NEPA + DEX3 (n = 85) | NEPA + DEX4 (n = 83) |
|---|---|---|---|
| Age, yr | |||
| Mean ± SD | 63.9 ± 7.2 | 62.7 ± 7.9 | 63.3 ± 8.2 |
| Median (range) | 66 (44–79) | 63 (34–77) | 64 (40–76) |
| Gender, n (%) | |||
| Male | 60 (71.4) | 51 (60) | 58 (69.9) |
| Female | 24 (28.6) | 34 (40) | 25 (30.1) |
| BMI (kg/m2), mean ± SD | 24.7 ± 4.2 | 24.6 ± 4.2 | 25 ± 4.0 |
| ECOG score, n (%) | |||
| 0 | 66 (78.6) | 70 (82.4) | 62 (74.7) |
| 1 | 18 (21.4) | 15 (17.6) | 21 (25.3) |
| Cisplatin | |||
| Mean ± SD | 75 ± 4.2 | 75.3 ± 4.4 | 74.3 ± 5.9 |
| Dose 70 mg/m2, n (%) | 20 (23.8) | 21 (24.7) | 21a (25.6) |
| Dose >70 mg/m2, n (%) | 64 (76.2) | 64 (75.3) | 61 (74.4) |
| Concomitant chemotherapy, n (%) | |||
| Pemetrexed | 37 (44.0) | 42 (49.4) | 44 (53.0) |
| Gemcitabine | 22 (26.2) | 21 (24.7) | 22 (26.5) |
| Vinorelbine | 21 (25.0) | 18 (21.2) | 14 (16.9) |
| Other | 4 (4.8) | 4 (4.7) | 3 (3.6) |
a
One patient received cisplatin dose <70 mg/m2 in the DEX4 arm.
Abbreviations: BMI, body mass index; DEX1, dexamethasone day 1; DEX3, dexamethasone day 1 to 3; DEX4, dexamethasone day 1 to 4; ECOG, Eastern Cooperative Oncology Group; NEPA, fixed‐dose combination of netupitant and palonosetron.